Blockchain Registration Transaction Record

Kairos Pharma Issues Shareholder Letter Outlining Progress and Strategic Developments

Kairos Pharma updates progress on ENV105 clinical trials for prostate and lung cancers, highlighting advancements in oncology therapeutics. CEO John Yu, M.D., shares strategic developments in a shareholder letter, underscoring the company's strong financial position and IP portfolio.

Kairos Pharma Issues Shareholder Letter Outlining Progress and Strategic Developments

This news matters as it showcases Kairos Pharma's advancements in oncology therapeutics, particularly in overcoming drug resistance and immune suppression in cancer. The progress in ENV105 clinical trials for various cancer types signifies potential breakthroughs in addressing unmet medical needs, offering hope for improved treatment outcomes for patients.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x0552b454aaa4a36d04f6711c3747c772627aa8221dd517f7511e3f52e6df04bd
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintcalmc60_-11b56ea13aefbdbb4f9964a47b9b4772